Since enhanced kinase activity appears to be a key factor in the progression of familial PD [18] from a pharmacological standpoint, this is the most straightforward strategy to address LRRK2 clinically in all PD-causing mutations. This evidence concerns the gene LRRK2 and Parkinson disease.